AstraZeneca Pharma India Limited (IN:ASTRAZEN)
:ASTRAZEN
Top Page
AstraZeneca Pharma India Limited
(ASTRAZEN)
Select Model
Select Model
Rating:70Outperform
Price Target:
₹8,861.00
▲(5.09% Upside)
Action:UpgradedDate:10/01/25
AstraZeneca Pharma India Limited's strong financial performance, characterized by consistent revenue growth and solid cash flow management, is the primary driver of its stock score. However, the high P/E ratio suggests the stock may be overvalued, which, along with neutral technical indicators, tempers the overall score.
Positive Factors
Revenue Growth
Sustained revenue growth over multiple years signals durable demand and stronger commercial traction in India across core therapy areas. A near-doubling of revenue indicates expanding market penetration and product uptake, supporting longer-term scale economics and reinvestment capacity.
Negative Factors
Declining Return on Equity
A pronounced fall in ROE indicates the company is generating lower profitability from shareholders' capital, suggesting either margin compression or capital intensity rising faster than returns. Persistently lower ROE can limit ability to deliver attractive long-term returns unless operational efficiency improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth over multiple years signals durable demand and stronger commercial traction in India across core therapy areas. A near-doubling of revenue indicates expanding market penetration and product uptake, supporting longer-term scale economics and reinvestment capacity.
Read all positive factors
AstraZeneca Pharma India Limited (ASTRAZEN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹201.39B
Dividend Yield0.35%
Average Volume (3M)602.00
Price to Earnings (P/E)173.1
Beta (1Y)0.78
Revenue Growth35.14%
EPS Growth143.11%
CountryIN
Employees940
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)13.04
Shares Outstanding25,000,000
10 Day Avg. Volume682
30 Day Avg. Volume602
Financial Highlights & Ratios
PEG Ratio-6.48
Price to Book (P/B)27.56
Price to Sales (P/S)12.39
P/FCF Ratio333.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AstraZeneca Pharma India Limited Business Overview & Revenue Model
Company Description
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta,...
How the Company Makes Money
AstraZeneca Pharma India Limited primarily makes money by commercializing (marketing, distributing, and selling) AstraZeneca’s prescription pharmaceutical brands in India. Revenue is mainly generated from domestic sales of branded medicines to hea...
AstraZeneca Pharma India Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
90
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.03B | 17.13B | 12.96B | 10.03B | 8.06B | 8.09B |
| Gross Profit | 8.39B | 7.13B | 6.22B | 5.78B | 4.48B | 4.78B |
| EBITDA | 3.16B | 1.98B | 2.36B | 1.51B | 1.01B | 1.48B |
| Net Income | 1.99B | 1.16B | 1.62B | 992.90M | 616.00M | 933.00M |
Balance Sheet | ||||||
| Total Assets | 16.15B | 15.18B | 10.78B | 9.85B | 8.57B | 7.75B |
| Cash, Cash Equivalents and Short-Term Investments | 4.10B | 5.53B | 5.06B | 5.00B | 4.48B | 3.52B |
| Total Debt | 347.90M | 357.30M | 45.90M | 72.14M | 86.30M | 121.40M |
| Total Liabilities | 8.16B | 7.48B | 3.66B | 3.96B | 3.45B | 3.19B |
| Stockholders Equity | 7.99B | 7.70B | 7.12B | 5.89B | 5.11B | 4.56B |
Cash Flow | ||||||
| Free Cash Flow | -660.20M | 636.10M | 171.10M | 497.70M | 911.80M | 970.70M |
| Operating Cash Flow | -657.30M | 653.60M | 278.70M | 582.90M | 1.01B | 1.05B |
| Investing Cash Flow | 135.40M | 308.00M | 217.40M | 181.10M | 47.40M | 1.73B |
| Financing Cash Flow | -845.60M | -655.90M | -443.80M | -244.80M | -94.60M | -89.70M |
AstraZeneca Pharma India Limited Technical Analysis
Negative
8431.70
Price Trends
8521.50
Negative
8693.99
Negative
8851.14
Negative
Market Momentum
-211.57
Positive
43.41
Neutral
28.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTRAZEN, the sentiment is Negative. The current price of 8431.7 is above the 20-day moving average (MA) of 8212.23, below the 50-day MA of 8521.50, and below the 200-day MA of 8851.14, indicating a bearish trend. The MACD of -211.57 indicates Positive momentum. The RSI at 43.41 is Neutral, neither overbought nor oversold. The STOCH value of 28.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTRAZEN.
AstraZeneca Pharma India Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹641.97B | 25.97 | ― | 0.80% | 9.32% | 11.25% | |
70 Outperform | ₹201.39B | 173.10 | ― | 0.35% | 35.14% | 143.11% | |
63 Neutral | ₹399.85B | 35.44 | ― | 2.16% | 4.17% | 41.51% | |
53 Neutral | ₹612.12B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ASTRAZEN
AstraZeneca Pharma India Limited
8,055.80
-392.80
-4.65%
IN:ALKEM
Alkem Laboratories Ltd.
5,369.20
535.84
11.09%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,360.30
-351.46
-12.96%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,169.10
794.92
57.85%
AstraZeneca Pharma India Limited Corporate Events
AstraZeneca Pharma India bolsters oncology and market access leadership
Mar 31, 2026
AstraZeneca Pharma India Limited has strengthened its leadership team by appointing clinical oncologist Dr. Shashank Srinivasan as Medical Director for its Oncology Business Unit, effective April 1, 2026. Dr. Srinivasan brings extensive experience...
AstraZeneca Pharma India Clears Related-Party Deals via Postal Ballot
Mar 31, 2026
AstraZeneca Pharma India Limited has announced that ordinary resolutions seeking shareholder approval for material related-party transactions have been passed by non-related members through a postal ballot, with the requisite majority. The company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.